The lack of therapeutic benefit of adding hydroxyurea to highly active antiretroviral therapy (HAART) [1]

Journal of Acquired Immune Deficiency Syndromes

Volumn 30, Issue 3, 2002, Pages 363-364

  Gonzalez, Omar Y ^a   Jovanovich, John F ^a   Mayers, Douglas L ^a   Musher, Daniel M ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; DIDANOSINE; GANCICLOVIR; HYDROXYUREA; NUCLEOSIDE ANALOG; VIRUS RNA;

ANEMIA; ANTIVIRAL ACTIVITY; CONTROLLED STUDY; DRUG EFFICACY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTOPENIA; VIRUS LOAD;

EID: 0036639971     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200207010-00014     Document Type: Letter

References (18)

1. Pharmacokinetics of hydroxyurea in patients infected with human immunodeficiency virus Type I
2. Panel on clinical practice for the treatment of HIV infection
3. A placebo-controlled trial of didanosine pluse stavudine, with and without hydroxyurea, for HIV infection. The Swiss HIV Cohort Study
4. Hydroxyurea treatment in HIV-infected patients
5. Hydroxyurea as an inhibitor of human immunodeficiency virus-Type I replication
6. Anti-human immunodeficiency virus Type 1 activity of hydroxyurea in combination with 2′, 3′dideoxynucleosides
7. A pilot study of hydroxyurea among patients with advanced human immunodeficiency virus (HIV) disease receiving chronic didanosine therapy: Canadian HIV Trials Network Protocol 080
8. Low levels of deoxynucleotides in peripheral blood lymphocytes: A strategy to inhibit human immunodeficiency virus type 1 replication
9. Hydroxyurea for the therapy of HIV infection: From antiviral to immune-modulating effects
10. Is hydroxyurea for real? Or, La Strada Nuova
11. Hydroxyurea for HIV infection
12. Hydroxyurea and HIV-1 viraemia
13. Preliminary results of a randomized trail comparing D4T/ddI/abacavir/efavirenz to the same combination plus hydroxyurea with or without IL-2 as salvage regimens (The HYDILE Study)
14. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease
15. Natural history of HIV-1 disease
16. An overview of the clincal experience with hydroxyurea
17. Hematologic responses of patients with sickle cell disease to treatment with hydroxyurea
18. Effects of treatment intensification with hydroxyurea in HIV-infected patients with virologic suppression